NLRP3 inflammasome as a treatment target in atherosclerosis: A focus on statin therapy

Negin Parsamanesh, Maryam Moossavi, Afsane Bahrami, Mohammad Fereidouni, George Barreto, Amirhossein Sahebkar

Research output: Contribution to journalReview articlepeer-review

Abstract

Activation of NOD-like receptor (NLR)family and pyrin domain containing 3 (NLRP3)inflammasome contributes to inflammation and may lead to atherosclerosis. The NLRP3 inflammasome as a molecular platform regulates the activation of ATP signaling, K+ efflux, cathepsin-B activity, lysosomal function and pro-inflammatory cytokines (i.e. IL-1β and IL-18). Statins has been widely prescribed for the treatment of hyperlipidemia and cardiovascular diseases. In addition to lipid-lowering effect, statins have immunomodulatory, anti-inflammatory, antioxidant and antiapoptotic functions. An increasing number of studies indicated NLRP3 inflammasome and their downstream mediators as important targets for statin drugs in inflammatory diseases. In this review, we discussed different aspect of the NLRP3 inflammasome signaling pathways and focused on the effect of statin drugs on NLRP3 inflammasomes in association to atherosclerosis in order to elucidate possible targets for future research and clinical settings.

Original languageEnglish
Pages (from-to)146-155
Number of pages10
JournalInternational Immunopharmacology
Volume73
DOIs
Publication statusPublished - Aug 2019
Externally publishedYes

Keywords

  • Acute coronary syndrome
  • Coronary atherosclerosis
  • Inflammation
  • NLRP3
  • NOD-like receptor

Fingerprint

Dive into the research topics of 'NLRP3 inflammasome as a treatment target in atherosclerosis: A focus on statin therapy'. Together they form a unique fingerprint.

Cite this